Enterprise Value
2.022B
Cash
552M
Avg Qtr Burn
-114.7M
Short % of Float
5.42%
Insider Ownership
4.67%
Institutional Own.
98.58%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DTX401 Details Glycogen Storage Disease Type Ia | Phase 3 Data readout | |
DTX301 Details Ornithine transcarbmylase deficiency | Phase 3 Update | |
Setrusumab (UGX143) Details Osteogenesis imperfecta | Phase 2/3 Data readout | |
UX701 Details Rare diseases, Wilson's disease | Phase 1/2 Data readout | |
UX053 Details Rare diseases, glycogen storage disease type III | Phase 1/2 Data readout | |
GTX-102 Details Angelman Syndrome | Phase 1/2 Interim update |